Bailout To Cost $200 Billion Less Than Expected
On the upside
IXYS will acquire Zilog (Nasdaq: ZILG) in a $62.4 million deal.
A Barron's article over the weekend said that Sprint (NYSE: S) stock was undervalued by as much as 50%.
McDermott International (NYSE: MDR) announced that it will spin-off its Babcock & Wilcox business.
On the downside
Allos Therapeutics (Nasdaq: ALTH) defended its lymphoma treatment Folotyn as rival Celgene (Nasdaq: CELG) prepared to launch its lymphoma drug Istodax which it acquired from Gloucester Pharmaceuticals.
Soleil downgraded Zale (NYSE: ZLC) to a Sell rating.
Krispy Kreme (NYSE: KKD) narrowed third quarter losses but revenue dropped.
In the broad market, advancing issues outpaced decliners by a margin of more than 5 to 3 on the NYSE and by nearly 5 to 4 on Nasdaq. The Russell 2000 which tracks small cap stocks rose 2 points to 605.

